The Experts below are selected from a list of 21 Experts worldwide ranked by ideXlab platform

Berthold Rzany - One of the best experts on this subject based on the ideXlab platform.

  • Efficacy and safety of Methantheline Bromide (Vagantin®) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo‐controlled trial
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2012
    Co-Authors: C. Müller, A. Berensmeier, H. Hamm, Thomas Dirschka, Kristian Reich, T. Fischer, Berthold Rzany
    Abstract:

    Background  Focal hyperhidrosis can severely affect quality of life. So far, knowledge on the effect of systemic therapy of focal hyperhidrosis is limited. Objective  To assess the efficacy and safety of Methantheline Bromide (MB) in the treatment of axillary and palmar-axillary hyperhidrosis. Methods  A multicenter controlled randomized double-blind clinical trial was conducted in patients with axillary or palmar-axillary hyperhidrosis defined by a sweat production >50 mg/5 min. Patients received 3 × 50 mg MB daily or placebo over a period of 28 ± 1 days. Main outcome criterion was the reduction of sweat as measured by gravimetry on day 28 ± 1. Quality of life was assessed by Dermatology Life Quality Index (DLQI) and Hyperhidrosis Disease Severity Score (HDSS). Results  A total of 339 patients were randomly assigned to receive MB or placebo. On day 28 ± 1, the mean axillary sweat production was 99 mg for MB and 130 mg for placebo compared with 168 mg and 161 mg respectively at baseline (P = 0.004). Patient′s HDSS score decreased in the MB group from 3.2 to 2.4 compared with 3.2 to 2.7 for placebo (P = 0.002). Similar results could be obtained for the DLQI with 9.7 for MB and 12.2 for placebo, which decreased from 16.4 or 17 respectively (P = 0.003). Tolerability was good for both groups. The most frequent adverse event was dry mouth. Conclusion  Fifty milligrams Methantheline Bromide three times a day is an effective and safe treatment of axillary hyperhidrosis.

Carolyn A. Young - One of the best experts on this subject based on the ideXlab platform.

  • The Cochrane Library - Anticholinergics for urinary symptoms in multiple sclerosis
    The Cochrane database of systematic reviews, 2009
    Co-Authors: Richard Nicholas, Tim Friede, Sally Hollis, Carolyn A. Young
    Abstract:

    Background Multiple Sclerosis (MS) is the commonest physically disabling chronic neurological disease affecting young people. Urinary symptoms are present in about 68% of people with MS but their basis has a number of potential aetiologies that can change with time. Objectives To assess the absolute and comparative efficacy, tolerability and safety of anticholinergic agents in MS patients. Search strategy We searched the Cochrane Multiple Sclerosis Group Specialised Trials Register, the Cochrane Central Register of Controlled Trials (The Cochrane Library 2008, Issue1), MEDLINE (January 1966 to January 2008), EMBASE (January 1974 to January 2008), supplemented with search of reference lists, personal communication with authors and relevant drug manufacturers. Selection criteria Randomised trials and cross-over trials (blinded and unblinded) that are either placebo-controlled or comparing two or more treatments. All four review authors independently assessed eligibility and trial quality, and extracted data. Data collection and analysis Data were processed as described in the Cochrane Handbook for Systematic Reviews of Interventions. Main results Our search strategy identified 33 articles of which thirty were excluded. Three single centre trials were included. No details were given regarding randomisation and blinding in the first two trials but side effects were frequent with all treatments. The first (Hebjorn 1977) was a double blind randomised crossover trial. Thirty four persons with MS received three drugs Methantheline Bromide, Flavoxate Chloride and Meladrazine Tartrate each for 14 days, washout periods were not mentioned. Median volume measurements at the first bladder contraction were statistically significant at a 5% level for Methantheline Bromide only compared to no treatment. The second (Gajewski 1986) was a prospective parallel group randomised study. Thirty four persons with MS were treated for 6-8 weeks with Oxybutynin (19 subjects) or Propantheline (15 subjects). For frequency, nocturia, urgency, and urge incontinence differences in symptom grade in favour of Oxybutynin were found. However, only for frequency the difference was statistically significant at 5% level. The third (Fader 2007) was a double blind crossover trial. Sixty four persons with MS received oral Oxybutynin or intravesical Atropine for 14 days. Details of randomisation and blinding were given. There was no significant difference between the two treatments in any efficacy outcome measure. Side effects and QOL scores showed significant differences in favour of atropine. Authors' conclusions From the available evidence we cannot advocate the use of anticholinergics in MS.

C. Müller - One of the best experts on this subject based on the ideXlab platform.

  • Efficacy and safety of Methantheline Bromide (Vagantin®) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo‐controlled trial
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2012
    Co-Authors: C. Müller, A. Berensmeier, H. Hamm, Thomas Dirschka, Kristian Reich, T. Fischer, Berthold Rzany
    Abstract:

    Background  Focal hyperhidrosis can severely affect quality of life. So far, knowledge on the effect of systemic therapy of focal hyperhidrosis is limited. Objective  To assess the efficacy and safety of Methantheline Bromide (MB) in the treatment of axillary and palmar-axillary hyperhidrosis. Methods  A multicenter controlled randomized double-blind clinical trial was conducted in patients with axillary or palmar-axillary hyperhidrosis defined by a sweat production >50 mg/5 min. Patients received 3 × 50 mg MB daily or placebo over a period of 28 ± 1 days. Main outcome criterion was the reduction of sweat as measured by gravimetry on day 28 ± 1. Quality of life was assessed by Dermatology Life Quality Index (DLQI) and Hyperhidrosis Disease Severity Score (HDSS). Results  A total of 339 patients were randomly assigned to receive MB or placebo. On day 28 ± 1, the mean axillary sweat production was 99 mg for MB and 130 mg for placebo compared with 168 mg and 161 mg respectively at baseline (P = 0.004). Patient′s HDSS score decreased in the MB group from 3.2 to 2.4 compared with 3.2 to 2.7 for placebo (P = 0.002). Similar results could be obtained for the DLQI with 9.7 for MB and 12.2 for placebo, which decreased from 16.4 or 17 respectively (P = 0.003). Tolerability was good for both groups. The most frequent adverse event was dry mouth. Conclusion  Fifty milligrams Methantheline Bromide three times a day is an effective and safe treatment of axillary hyperhidrosis.

Richard Nicholas - One of the best experts on this subject based on the ideXlab platform.

  • The Cochrane Library - Anticholinergics for urinary symptoms in multiple sclerosis
    The Cochrane database of systematic reviews, 2009
    Co-Authors: Richard Nicholas, Tim Friede, Sally Hollis, Carolyn A. Young
    Abstract:

    Background Multiple Sclerosis (MS) is the commonest physically disabling chronic neurological disease affecting young people. Urinary symptoms are present in about 68% of people with MS but their basis has a number of potential aetiologies that can change with time. Objectives To assess the absolute and comparative efficacy, tolerability and safety of anticholinergic agents in MS patients. Search strategy We searched the Cochrane Multiple Sclerosis Group Specialised Trials Register, the Cochrane Central Register of Controlled Trials (The Cochrane Library 2008, Issue1), MEDLINE (January 1966 to January 2008), EMBASE (January 1974 to January 2008), supplemented with search of reference lists, personal communication with authors and relevant drug manufacturers. Selection criteria Randomised trials and cross-over trials (blinded and unblinded) that are either placebo-controlled or comparing two or more treatments. All four review authors independently assessed eligibility and trial quality, and extracted data. Data collection and analysis Data were processed as described in the Cochrane Handbook for Systematic Reviews of Interventions. Main results Our search strategy identified 33 articles of which thirty were excluded. Three single centre trials were included. No details were given regarding randomisation and blinding in the first two trials but side effects were frequent with all treatments. The first (Hebjorn 1977) was a double blind randomised crossover trial. Thirty four persons with MS received three drugs Methantheline Bromide, Flavoxate Chloride and Meladrazine Tartrate each for 14 days, washout periods were not mentioned. Median volume measurements at the first bladder contraction were statistically significant at a 5% level for Methantheline Bromide only compared to no treatment. The second (Gajewski 1986) was a prospective parallel group randomised study. Thirty four persons with MS were treated for 6-8 weeks with Oxybutynin (19 subjects) or Propantheline (15 subjects). For frequency, nocturia, urgency, and urge incontinence differences in symptom grade in favour of Oxybutynin were found. However, only for frequency the difference was statistically significant at 5% level. The third (Fader 2007) was a double blind crossover trial. Sixty four persons with MS received oral Oxybutynin or intravesical Atropine for 14 days. Details of randomisation and blinding were given. There was no significant difference between the two treatments in any efficacy outcome measure. Side effects and QOL scores showed significant differences in favour of atropine. Authors' conclusions From the available evidence we cannot advocate the use of anticholinergics in MS.

H. Hamm - One of the best experts on this subject based on the ideXlab platform.

  • Efficacy and safety of Methantheline Bromide (Vagantin®) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo‐controlled trial
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2012
    Co-Authors: C. Müller, A. Berensmeier, H. Hamm, Thomas Dirschka, Kristian Reich, T. Fischer, Berthold Rzany
    Abstract:

    Background  Focal hyperhidrosis can severely affect quality of life. So far, knowledge on the effect of systemic therapy of focal hyperhidrosis is limited. Objective  To assess the efficacy and safety of Methantheline Bromide (MB) in the treatment of axillary and palmar-axillary hyperhidrosis. Methods  A multicenter controlled randomized double-blind clinical trial was conducted in patients with axillary or palmar-axillary hyperhidrosis defined by a sweat production >50 mg/5 min. Patients received 3 × 50 mg MB daily or placebo over a period of 28 ± 1 days. Main outcome criterion was the reduction of sweat as measured by gravimetry on day 28 ± 1. Quality of life was assessed by Dermatology Life Quality Index (DLQI) and Hyperhidrosis Disease Severity Score (HDSS). Results  A total of 339 patients were randomly assigned to receive MB or placebo. On day 28 ± 1, the mean axillary sweat production was 99 mg for MB and 130 mg for placebo compared with 168 mg and 161 mg respectively at baseline (P = 0.004). Patient′s HDSS score decreased in the MB group from 3.2 to 2.4 compared with 3.2 to 2.7 for placebo (P = 0.002). Similar results could be obtained for the DLQI with 9.7 for MB and 12.2 for placebo, which decreased from 16.4 or 17 respectively (P = 0.003). Tolerability was good for both groups. The most frequent adverse event was dry mouth. Conclusion  Fifty milligrams Methantheline Bromide three times a day is an effective and safe treatment of axillary hyperhidrosis.